EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Allogenic haematopoietic stem cell transplantation in VEXAS: A review of 33 patients

Syed B Ali, Carmelo Gurnari

Clinical Rheumatology · 2024-11 · 43 (11) · 3565-3575

DOI: 10.1007/s10067-024-07160-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Rheumatology, online erschienen am 30.09.2024. Verfasst von Syed B Ali und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and Allergy, Flinders Medical Centre, Bedford Park, South Australia, Australia. syed.ali@sa.gov.au. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Ubiquitin-Activating Enzymes, Transplantation, Homologous, Transplantation Conditioning. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Flinders University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vacuolation, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a multisystem disease due to a genetic mutation in the ubiquitin-activating enzyme ( UBA1 ). Allogeneic haematopoietic stem cell transplantation (allo-HSCT) offers both therapeutic and cure but also carries significant risks. A review of VEXAS and HSCT cases was undertaken. Thirty-three patients were identified; majority males ( n = 32, 97.0%), median time from symptoms to HSCT: 3 years (IQR 2.0–4.8) and median age of 59 years (IQR 52.5–65.5). UBA1 mutation Met41Thr was most common (11/32, 34.4%). The median variant allele frequency was 56.5% (IQR 43.0–73.5) with no correlation with increasing age. Prior to HSCT, 4.5 (IQR 2.8–6) treatments were trialled. Peripheral blood HSCT (30/31, 96.8%) and HLA-matched, unrelated donor (18/32, 56.3%) were most common. Conditioning regimens varied, with reduced intensity treatment with fludarabine as a co-agent most frequently administered (12/31, 38.7%). Both acute and/or chronic GVHD (18/32, 56.3%) and infections were common (12/32, 37.5%). Overall, 27 individuals (81.8%) were alive, and those undergoing HSCT prospectively had median follow up of 9 months (IQR 3.8–14.4). Of the six deceased, infection was implicated in four. In 11 cases with post-HSCT molecular data, a complete eradication of UBA1 mutation was reported. In summary, while consensus treatment strategy regarding VEXAS is lacking, this review highlights HSCT may remain not only a therapeutic option but also enable cure. However, considerations regarding comorbidities, concurrent haematological disorders as well as overall risks of GVHD and infections need to be made. Key points • Very few reported prospective cases of VEXAS and allogeneic haematopoietic stem cell transplantation (allo-HSCT) have been reported. • While risks of graft versus host disease and infection remain barriers, this treatment modality remains an option for selected patients. • Allo-HSCT is the only treatment strategy which can remove the UBA1 mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationUbiquitin-Activating EnzymesTransplantation, HomologousTransplantation ConditioningHumansMaleMiddle AgedFemaleMutationAgedGraft vs Host DiseaseAdultGenetic Diseases, X-Linked

Stichwörter der Autor:innen

Allogenic stem cell transplantationMyelodysplatic syndromeSomatic mutationTransplantationVEXAS Syndrome

Substanzen

Ubiquitin-Activating EnzymesUBA1 protein, human

Autor:innen und Institutionen

  • Department of Clinical Immunology and Allergy, Flinders Medical Centre, Bedford Park, South Australia, Australia. syed.ali@sa.gov.au.
  • School of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia. syed.ali@sa.gov.au.
  • Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, Adelaide, South Australia, Australia. syed.ali@sa.gov.au.
  • School of Medicine and Biomedical Sciences, University of Adelaide, Adelaide, South Australia, Australia. syed.ali@sa.gov.au.
  • Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Förderung

  • Flinders University

Zitieren

APA

Ali, S. B., & Gurnari, C. (2024). Allogenic haematopoietic stem cell transplantation in VEXAS: A review of 33 patients. Clinical Rheumatology, 43(11), 3565-3575. https://doi.org/10.1007/s10067-024-07160-7

Vancouver

Ali SB, Gurnari C. Allogenic haematopoietic stem cell transplantation in VEXAS: A review of 33 patients. Clinical Rheumatology. 2024;43(11):3565-3575. doi:10.1007/s10067-024-07160-7

BibTeX
@article{Ali2024,
  author = {Ali, Syed B and Gurnari, Carmelo},
  title = {Allogenic haematopoietic stem cell transplantation in VEXAS: A review of 33 patients},
  journal = {Clinical Rheumatology},
  year = {2024},
  volume = {43},
  number = {11},
  pages = {3565--3575},
  doi = {10.1007/s10067-024-07160-7}
}
Kostenlos starten →